Heres How 23andMe Hopes to Make Drugs From Your Spit Samples

TIME Health medicine Heres How 23andMe Hopes to Make Drugs From Your Spit Samples The company is making a bold move to enter the drug-making business by using the genetic information donated by its clients

On March 12, 23andMe, the genetic testing company best known for analyzing your DNA from a sample of spit, announced the creation of a new therapeutics group. The groups mission: to find and develop drugs from the worlds largest database of human genetic material.

Thats a huge shift for the company, which must now build a research and development arm from scratch. Richard Scheller, formerly of the biotechnology corporation Genentech, will lead the group and will also be 23andMes chief science officer.

Scheller admits that for now, hes the therapeutics groups only member. But soon after he starts on April 1, he anticipates that things will move quickly, as they do in the genetics world. Thats what attracted him to 23andMe after overseeing early drug development at Genentech for 14 years. Ive seen over the last couple of years how human genetics has impacted the way Genentech does drug discovery, and I thought it might be fun and interesting to work in an unrestricted way with the worlds largest human genetic database, he says. The questions we will ask are research based, but we could identify a drug target extremely quickly. I believe there is the real possibility to do really, really great things for people with unmet medical needs.

MORE: Genetic Testing Company 23andMe Finds New Revenue With Big Pharma

More than 850,000 people have paid 23andMe to sequence their DNA since the company launched in 2006 until 2013, when the Food and Drug Administration requested that the company stop selling its medical genetic information services over concerns that their marketing claims werent supported by strong enough evidence about how the genetic information influenced human health. The company still retains that genetic information and continues to sell kits, but provides only non-medical information now while it continues to work with the FDA on further regulatory issues.

That experience transformed the company, as CEO Anne Wojcicki said to TIME earlier this year. Since then, the company has expanded its collaborations with pharmaceutical companies to access its database. The latest addition of drug development is a further evolution in the companys identity.

Of those who have sent in samples, 80% have agreed to allow their genetic information to be used for research purposes. Thats the database that Scheller is eager to investigate. While at Genentech, he helped broker a collaboration between the biotech firm and 23andMe in which Genentech would have access just to the genetic testing companys Parkinsons disease patients, to search for any genetic clues to new therapies. Now, he says, I plan on asking hundreds or maybe thousands of times more questions of the database than any pharmaceutical partner.

MORE: 23andMe Finds Genes for Motion Sickness

He will be looking, for example, at whether patients who develop a certain disease tend to have specific hallmark genetic changes in their DNA, which could serve as potential launching points for new drugs. Or he might focus on the extreme outliers: people who have advanced cancer, for example, but somehow survive, or those who seem to succumb early. Mining their genomes might yield valuable information about what makes diseases more or less aggressive, and might become targets for drugs as well.

Visit link:
Heres How 23andMe Hopes to Make Drugs From Your Spit Samples